Skip to content

Kopin KOPN Deferred Tax Assets Research And Development Expense Amortization

Deferred Tax Assets Research And Development Expense Amortization at other companies

MAG
MagneraMAGN
$10M+11.1%
Immix Biopharma, Inc. logo
Immix Biopharma, Inc.IMMX
$3.03M-45.9%
NioCorp Developments Ltd. logo
NioCorp Developments Ltd.NB
$1.3M-8.7%
Sharplink, Inc.
 logo
Sharplink, Inc. SBET
$158K
Minerals Technologies logo
Minerals TechnologiesMTX
$12.6M+14.5%
Nuvation Bio logo
Nuvation BioNUVB
$78.79M-19.0%

Other financials

Income statement

See full
Revenue$10.6M+0.1%
Operating income-$6.0M-53.2%
Net income-$3.8M-20.5%
EPS (diluted)-$0.020.0%

Balance sheet

See full
Cash & equivalents$34.1M+123%
Total debt$1.3M-31.7%
Total equity$60.8M+194%
Total assets$102.4M+57.5%

Cash flow

See full
Operating cash flow-$810.7K+76.3%
CapEx$1.3M+160%
Free cash flow-$2.1M+46.0%

Valuation

See full
Market cap$702.29M+175%
Enterprise value$669.47M+177%
P/E356.9×
P/S17.9×+12.8×

Profitability

See full
Gross margin46.7%
Operating margin-30.3%+2.4pp
Net margin5%+2.7pp
FCF margin-38.6%+13.3pp

Returns & leverage

See full
Return on equity4.8%+2.5pp
Debt / equity-0.1×
Current ratio2.6×+1.2×

Where this comes from

Reported directly by Kopin in its filing.

Tagged under the XBRL concept KOPN:DeferredTaxAssetsResearchAndDevelopmentExpenseAmortization.

The official record: Kopin’s 10-K, filed April 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Kopin's deferred tax assets research and development expense amortization.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Kopin's deferred tax assets research and development expense amortization?
Kopin (KOPN) reported deferred tax assets research and development expense amortization of $1.45M in Q4 2025.
What is the long-term trend for Kopin's deferred tax assets research and development expense amortization?
Over 3 years (2022 to 2025), Kopin's deferred tax assets research and development expense amortization has grown at a -8.7% compound annual growth rate (CAGR), from $1.9M to $1.45M.
What does deferred tax assets research and development expense amortization mean?
This metric quantifies the deferred tax assets resulting from the capitalization and subsequent amortization of research and development expenses for tax purposes. It highlights the future tax shield created by the company's investment in innovation and product development. This is a key indicator of how R&D spending impacts the company's long-term tax position and cash flow efficiency.